We areworking relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients
We are
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients
Pipeline
Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.
| Preclinical | Clinical | Marketed | |||||
| Indication | Proof of Principle | Safety | Dose Optimization | Clinical Activity | Pivotal | Commercial | |
|---|---|---|---|---|---|---|---|
| Heme Malignancies | |||||||
| Emavusertib* IRAK4 |
IRAK4-driven Leukemia (AML/MDS) | TakeAim Leukemia1 | |||||
| Emavusertib* IRAK4 |
IRAK4-driven Lymphoma (NHL, CLL, WM) | TakeAim Lymphoma | |||||
| Fimepinostat HDAC/PI3K |
MYC-altered Cancers | ||||||
| Immune Checkpoint Inhibitors | |||||||
| CI-8993** VISTA |
VISTA-expressing Cancers | ||||||
| CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | ||||||
| CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | ||||||
| Approved Drug | |||||||
| Erivedge*** Hedgehog |
Basal Cell Carcinoma | ||||||
| Drug | Indication | Stage |
| Heme Malignancies | Emavusertib* IRAK4 |
IRAK4-driven Leukemia (AML/MDS) | Clinical Activity |
| Emavusertib* IRAK4 |
IRAK4-driven Lymphoma (NHL, CLL, WM) | Clinical Activity |
| Fimepinostat HDAC/PI3K |
MYC-altered Cancers | Clinical Activity |
| Immune Checkpoint Inhibitors | CI-8993** VISTA |
VISTA-expressing Cancers | Safety |
| CA-327* TIM3/PDL1 |
PDL1/TIM3-expressing Cancers | Proof of Principle |
| CA-170* VISTA/PDL1 |
PDL1/VISTA-expressing Cancers | Clinical Activity |
| Approved Drug | Erivedge*** Hedgehog |
Basal Cell Carcinoma | Commercial |
* IP licensed from Aurigene
** Exclusive option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)
1) In April 2022 the U.S. Food and Drug Administration placed both TakeAim studies (Leukemia and Lymphoma) on partial clinical hold during which no new patients will be enrolled in the studies, and current study participants benefitting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower.
